IQ-AI’s Imaging Biometrics at the forefront of brain tumour analysis

0
23
  • IQ-AI starts trading on US OTC market
  • IQ-AI trebles in value after impressive run of updates
  • IQ-AI present their plans to finance brain tumour trial to evaluate efficacy of Gallium Maltolate
medical imaging graphic

Quick facts: IQ-AI Ltd

Follow

View company profile

IQAI was created to accelerate the translation and commercialisation of proven imaging technologies, from the laboratory to routine clinical use, that have potential to dramatically impact the quality of life for patients facing brain tumours and other chronic diseases.

Brain tumour patients and especially those diagnosed with glioblastoma multiforme (GBM) for example face a dismal prognosis. Despite tremendous global efforts that span decades, only incremental improvements have been made in survivability and progression free survival.

The unmet clinical need of GBM and other diseases motivates IQAI to continuously innovate and deliver validated products that benefit patients. Since its inception, the company has aggressively proliferated its product portfolio, accelerated product and technology development, and obtained market clearance for new global territories.

01 Sep 2021

(, ) () shares will begin trading on the OTCQB Venture Market in the United States from today under the ticker symbol “IQAIF”.

In a statement, the neuroimaging data specialist said its objective in listing its shares on the OTCQB is to provide more efficient access to a new and materially larger pool of prospective US investors.

Trevor Brown, chief executive, added: “The United States is home to some of the world’s most influential medical technology investors.

“By joining OTCQB, we now have an effective platform from which to reach a significantly larger investor audience and we look forward to providing investors in both the UK and the United States with regular progress updates at this exciting and pivotal time for the company.”

Read more

27 Aug 2021

(, ) () reported a doubling of revenue in the first half and said it expects this level of sales to continue for the rest of the year.

Revenue rose by 104% to GBP238,438 in the six months to end-June from GBP116,842 last year, while losses shrank by 44% to GBP207,135.

Read more

11 Jun 2021

IQ-AI Limited () said its synthetic T1+C (Gad-Free) software application was awarded a patent by the US Patent and Trademark Office.

The technology eliminates the need to intravenously inject contrast agent during medical imaging procedures, the company said, adding that the patent underscores the potential of artificial intelligence (AI), its ability to streamline workflows, enhance diagnostic quality, and improve patient safety.

Read more

09 Nov 2020

() is firing on all cylinders after a few busy weeks that saw its share price rocket three-fold.

The AIM-listed investor, which focuses on the tech sector, touched a five-year high last week after a triple dose of good news.

Read more

15 Apr 2021

Michael Schmainda, co-founder and CEO of ‘s () subsidiary Imaging Biometrics presents their plans to finance brain tumour trial to evaluate the safety and efficacy of Gallium Maltolate in the treatment of this disease.

This type of cancer, Glioblastoma is the most common and aggressive primary brain cancer and has limited treatment options and a dismal prognosis.

If the trial is successful IQAI intends to apply to the US Food and Drug Administration (FDA) for orphan drug status under the FDA’s orphan drug designation programme, which grants market exclusivity in the US for seven years following approval of the drug.

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is…

In exchange for publishing services rendered by the Company on behalf of named herein, including the promotion by the Company of in any Content on the Site, the Company receives from said issuer annual cash…

FOR OUR FULL DISCLAIMER CLICK HERE

IQ-AI present their plans to finance brain tumour trial to evaluate efficacy…

Michael Schmainda, co-founder and CEO of IQ-AI Limited’s (LON:IQAI) subsidiary Imaging Biometrics presents their plans to finance brain tumour trial to evaluate the safety and efficacy of Gallium Maltolate in the treatment of this disease.

This type of cancer, Glioblastoma is the most common…

on 15/4/21

4 min read

LEAVE A REPLY

Please enter your comment!
Please enter your name here